Affordability of oncology drugs: accuracy of budget impact estimations

References

• Schumock GT, Vermeulen LC. The rising cost of prescription drugs: causes and solutions. Pharmacotherapy. 2017;37:9–8.
   PubMed Web of Science ®Google Scholar
• Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14:381–390.
   PubMed Web of Science ®Google Scholar
• Green AK, Wood WA, Basch EM. Time to reassess the cancer compendia for off-label drug coverage in oncology. JAMA. 2016;316:1541–1542.
   Web of Science ®Google Scholar
• The Organisation for Economic Co-operation and Development (OECD). New health technologies: managing access, value and sustainability [Internet]; [cited 2018 Feb 7]. Available from: http://www.oecd-ilibrary.org/social-issues-migration-health/managing-new-technologies-in-health-care_9789264266438-en
   Google Scholar
• Cohen JP, Stolk E, Niezen M. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law. 2008;33:225–247.
   PubMed Web of Science ®Google Scholar
• Ghabri S, Mauskopf J. The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the USA: relationship to cost-effectiveness analysis and methodological challenges. Eur J Health Econ. 2018;19:173–175.
   PubMed Web of Science ®Google Scholar
• Niezen MG, de Bont A, Busschbach JJ, et al. Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int J Technol Assess Health Care. 2009;25:49–55.
   PubMed Web of Science ®Google Scholar
• Vooren K, van de DS, Curto A, et al. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014;12:33–40.
   Google Scholar
• Flume M, Bardou M, Capri S, et al. Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries. J Mark Access Health Policy. 2018;6:1478539.
   PubMedGoogle Scholar
• Barua S, Greenwald R, Grebely J, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the USA. Ann Intern Med. 2015;163:215.
   PubMed Web of Science ®Google Scholar
• Geenen JW, Boersma C, Klungel OH, et al. Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. Eur J Health Econ [Internet]. 2019;20:857–867. [cited 2019 May 2].
   Google Scholar
• Niezen MGH, Stolk EA, Steenhoek A, et al. Inequalities in oncology care: economic consequences of high cost drugs. Eur J Cancer. 2006;42:2887–2892.
   Web of Science ®Google Scholar
• American Society of Clinical Oncology.American society of clinical oncology position statement on addressing the affordability of cancer drugs. JOP. 2017. DOI:10.1200/JOP.2017.027359
   Google Scholar
• Keeping S, Deslandes PN, Haines KE, et al. Estimated versus observed expenditure associated with medicines recommended by the all wales medicines strategy group. Pharmacol Econ Open [Internet]. 2019;3:343–350. [cited 2019 Jan 22].
   Google Scholar
• Cha M, Rifai B, Sarraf P. Pharmaceutical forecasting: throwing darts? Nat Rev Drug Discov. 2013;12:737–738.
   PubMed Web of Science ®Google Scholar
• Broder MS, Zambrano JM, Lee J, Marken RS. Systematic bias in predictions of new drugs’ budget impact: analysis of a sample of recent US drug launches. Curr Med Res Opin. 2018 May 4;34(5):765–773.
   Google Scholar
• Staten-Generaal TK der. Geneesmiddelenbeleid; brief regering; vergoeding hepatitis C middel sovaldi met financieel arrangement [Internet]; 2014 [cited 2018 Oct 23]. Available from: https://zoek.officielebekendmakingen.nl/dossier/29477/kst-29477-296?resultIndex=252&sorttype=1&sortorder=4
   Google Scholar
• Zorginstituut Nederland. Grote budgetimpact effectief longkankermiddel durvalumab - nieuwsbericht [Internet];. 2019 [cited 2019 May 15]. Available from: https://www.zorginstituutnederland.nl/actueel/nieuws/2019/04/03/grote-budgetimpact-effectief-longkankermiddel-durvalumab
   Google Scholar
• Aggarwal A, Fojo T, Chamberlain C, et al. Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS cancer drugs fund. Ann Oncol. 2017;28:1738–1750.
   PubMed Web of Science ®Google Scholar
• Eichler H-G, Baird LG, Barker R, et al. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther. 2015;97:234–246.
   PubMed Web of Science ®Google Scholar
• Pauwels K, Huys I, Vogler S, et al. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol [Internet]. 2017;8. [cited 2019 Apr 4]. DOI:10.3389/fphar.2017.00171/full
   Web of Science ®Google Scholar
• Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg - publicatie [Internet]; 2016 [cited 2018 Oct 23]. Available from: https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg
   Google Scholar
• Zorginstituut Nederland. Kosteneffectiviteit in de praktijk [Internet]; 2015. Available from: https://www.zorginstituutnederland.nl/binaries/zinl/documenten/rapport/2015/06/26/kosteneffectiviteit-in-de-praktijk/Kosteneffectiviteit+in+de+praktijk.pdf
   Google Scholar
• Zorginstituut Nederland. GVS-advies sofosbuvir/ledipasvir (Harvoni®) bij chronische hepatitis C - advies [Internet]; 2015 [cited 2018 Mar 26]. Available from: https://www.zorginstituutnederland.nl/publicaties/adviezen/2015/05/18/gvs-advies-sofosbuvir-ledipasvir-harvoni-bij-chronische-hepatitis-c
   Google Scholar
• English - farminform [Internet]; [cited 2018 Apr 26]. Available from: https://www.farminform.nl/English
   Google Scholar
• G-standaard — Z-index [Internet]; [cited 2018 Aug 6]. Available from: https://www.z-index.nl/g-standaard
   Google Scholar
• PHARMO institute for drug outcomes research [Internet]. Pharmo; [cited 2018 Apr 26]. Available from: https://www.pharmo.nl/
   Google Scholar
• Ministerie van Volksgezondheid W en S. Home - zorginstituut nederland [Internet]; 2013 [cited 2018 May 1]. Available from: https://www.zorginstituutnederland.nl/
   Google Scholar
• European medicines agency - human medicines - European public assessment reports [Internet]; [cited 2018 May 3]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125
   Google Scholar
• Tofallis C. A better measure of relative prediction accuracy for model selection and model estimation [Internet]. Rochester, NY: Social Science Research Network; 2014 Jul. (Report No.: ID 2635088). Available from: https://papers.ssrn.com/abstract=2635088
   Google Scholar
• Tornqvist L, Vartia P, Vartia YO. How should relative changes be measured? Am Stat. 1985;39:43–46.
   Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2018. Available from: https://www.R-project.org/
   Google Scholar
• Wickham H. 2016. ggplot2: elegant graphics for data analysis [Internet]. New York: Springer-Verlag. Available from: http://ggplot2.org
   Google Scholar
• Zorginstituut Nederland. Trastuzumab (Herceptin) bij borstkanker met tumoren die een overexpressie van HER2 vertonen - rapport [Internet]; 2010 [cited 2018 Feb 20]. Available from: https://www.zorginstituutnederland.nl/publicaties/rapport/2010/04/26/trastuzumab-herceptin-bij-borstkanker-met-tumoren-die-een-overexpressie-van-her2-vertonen
   Google Scholar
• Morgan SG, Vogler S, Wagner AK. Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy. 2017;121:354–362.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17:5–14.
   PubMed Web of Science ®Google Scholar
• Zorginstituut Nederland. Format budget impact analyse GVS (voorheen kostenconsequentieraming) - publicatie [Internet]; 2016 [cited 2018 Mar 23]. Available from: https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/04/06/format-budget-impact-analyse-gvs-voorheen-kostenconsequentieraming
   Google Scholar